메뉴 건너뛰기
소속 기관 / 학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
고객센터 ENG
주제분류

논문 기본 정보

저자정보
출처
Springer Science and Business Media LLC EMBO Molecular Medicine 17(1)
오류 신고하기
표지

검색

    초록·키워드

    Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized primarily by the formation of heterotopic bone in connective tissue, such as tendon, muscle, ligament and fascia (Kaplan et al, 2024). The prevalence is approximately one in 2.5 million births, with over 2,500 cases diagnosed globally. Although rare, FOP is a severe and life-limiting condition with no current cure. Due to heterotopic bone formation in various organs, patients experience intense pain, restricted mobility, difficulty with eating and speaking, hearing loss, scoliosis, and impaired pulmonary function. The average lifespan for individuals with FOP is around 40 years. Therefore, studying the pathological mechanism and developing efficient drugs for FOP are highly demanding. In this issue of EMBO Molecular Medicine, Zhao et al, introduce bone morphogenetic protein 9 (BMP9) as a potential therapeutic target for FOP (Zhao et al, 2024). Q. Yuan and Q. Li discuss a potential therapeutic strategy for fibrodysplasia ossificans progressiva as reported by M. Ikeya and colleagues, in this issue of EMBO Mol Med.

    본문·목차

    최근 본 자료 전체보기